Sep 20, 2008|
This can be an apt exclamation to summarise the week gone by. It began with a groaning 'ouch', went to an 'aah', and ended with a 'wow', with the US government and central bank announcing a rescue plan to ease liquidity in the financial system. This week's action did not begin on Monday but on the preceding 'Black Sunday' when the world woke up to hear the demise of a revered Wall Street firm - Lehman Brothers, and stumbling of another - AIG.Also read - Once in a century crisis
As for the Indian markets, there was nothing special to do but follow global (read US) cues. There was deep desperation till about the middle of the week, as was also seen across key global markets. However, expectations of a financial rescue plan from the US government and central bankers raised the sinking ship yet again. And the Indian benchmark index (BSE-Sensex
) like its Asian peers romped home with a 700 points gain on Friday.
Also read - Simple survival lesson
Here is a pictorial representation of how the world and Indian equity markets performed during the week.
Indian stocks - Movers and shakers during the week
|Top gainers during the week (BSE-A Group)
||Change from 52-wk High
||0 / 0
||589 / 183
|Ind. Overseas Bank
||229 / 70
||1,436 / 419
||463 / 225
|Top losers during the week (BSE-A Group)
||547 / 166
||614 / 300
||220 / 99
||0 / 0
|Mundra Port & SEZ
||0 / 0
The week's biggest news
Pharma major Ranbaxy made news during the week, though for negative reasons. The stock was among the key losers (down almost 21% during the week). This was following the US FDA (US Food & Drug Administration) blacklisting 30 generic drugs being manufactured by the company at its plants in Dewas and Paonta Sahib. While the FDA did not impose a ban on the drugs or sought a withdrawal of the medicines from the US drug stores, what it had done was issue an import alert under which US officials may detain any products manufactured at these facilities of the company.
Considering that Ranbaxy manufactures some of its most important and high selling products at these two plants, the decision would have a significant impact on its revenues going forward. Following the FDA restriction, the company has moved fast to appoint the former New York City mayor Rudolph Giuliani to help respond to the order.
Unless and until Ranbaxy takes fast steps to adhere to the quality standards of the FDA, its credibility stands at stake. Interestingly, the promoters of the company have exited the company at a 'convenient' time to pocket a cool premium for their shares, while the minority shareholders are left to grapple with the wrongdoings of the company.Also read - Ranbaxy's perverse engineering
As Mr. Ajit Dayal, the co-founder of Equitymaster, recently exclaimed - "Ranbaxy has reminded us that, for all the exciting investment opportunities that exist in India, we swim naked much of the time. And, for all our speeches and TV talk of how modern our business operations are, a founder shareholder will always know a lot more than a 'minority'."Also read - Archives of Today's Markets
What to expect?Also read - How Wall Street failed?
We have just concluded was can truly be called the most dramatic week the world financial markets have seen during this decade. Some call the current crisis in the US the worst since the Great Depression of 1929. Some have even proclaimed the death of Wall Street. Mr. John Bogle, who was born five months before the stock-market crash of 1929 and in 1976 propounded the concept of index funds and, calls the US government as being 'punch drunk'.
He says, "We're playing a game of casino capitalism, interfering the way the market is working. The government seems punch drunk. It doesn't seem systematic."
Mr. Bogle sums up the entire situation very well - "We're in the most speculative market I've seen. We seem to be in the depths of despair one moment and the heights of optimism the next."
The US government's financial rescue plan has elicited 'wow' from market participants across the world. Will it turn into another 'ouch' remains to be seen.
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 19, 2017
Ever heard of Lindy Effect? Find out how you can use it to pick timeless stocks.
Aug 18, 2017
Buying the index now will hardly help make money in stocks even in ten years.
Aug 18, 2017
Donald J Trump, a wrasslin' fan, took a 'Holy Sh*t!' blow on Tuesday.
Aug 17, 2017
PersonalFN simplifies the mutual fund account statement for you.
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407